Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of adenocarcinoma of the prostate
• * Osseous metastases
• Androgen-independent disease
• Previously randomized to the docetaxel and placebo arm of protocol MDA-ID-030008 and has been removed from protocol due to disease progression
• * No more than 6 weeks since final treatment with docetaxel and placebo
• No uncontrolled brain metastases or spinal cord compression
• PATIENT CHARACTERISTICS:
• Age
• Any age
• Performance status
• Eastern Cooperative Oncology Group (ECOG) 0-3
• Life expectancy
• Not specified
• Hematopoietic
• Absolute granulocyte count ≥ 1,500/mm\^3
• Platelet count ≥ 75,000/mm\^3
• Hepatic
• Bilirubin ≤ 1.5 mg/dL
• alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤ 2 times upper limit of normal
• No chronic liver disease
• Renal
• Creatinine clearance ≥ 40 mL/min
• Cardiovascular
• No New York Heart Association class III or IV congestive heart failure
• No unstable angina
• No uncontrolled severe hypertension
• No myocardial infarction within the past 6 months
• Pulmonary
• No oxygen-dependent lung disease
• Other
• No prior dose-limiting toxicity with docetaxel requiring more than 2 dose reductions
• No severe hypersensitivity to docetaxel
• No prior dose-limiting toxicity with docetaxel requiring 1 dose reduction AND experienced recurrent grade 3 or 4 toxicity at the time of progression on MDA-ID-030008
• No uncontrolled diabetes mellitus
• No concurrent severe infection
• No overt psychosis, mental disability, or other incompetency that would preclude giving informed consent
• No history of non-compliance
• HIV negative
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent biologic therapy
• Chemotherapy
• See Disease Characteristics
• No other concurrent chemotherapy
• Endocrine therapy
• No concurrent second-line hormonal therapy
• Radiotherapy
• At least 3 weeks since prior radiotherapy
• No recent strontium chloride Sr 89 or samarium Sm 153 lexidronam pentasodium
• Surgery
• Recovered from prior surgery
• Other
• No other concurrent anticancer agents
• No other concurrent investigational agents
• No concurrent therapeutic warfarin
• * Concurrent mini-dose warfarin (1 mg/day) for central venous catheter prophylaxis allowed
• No concurrent grapefruit or grapefruit juice